Enanta Pharmaceuticals Stock Prediction and Forecast [ENTA]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 27 Sept 2025, 03:26 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Enanta Pharmaceuticals Stock Prediction and Forecast [ENTA]](https://i.ytimg.com/vi/SWaWnisGZmU/hqdefault.jpg)
AI-generated source summary
The video provides an analysis of Enanta Pharmaceuticals stock, updated as of September 28, 2025. Stock score data from September 26, 2025, assigned a hold or accumulate rank to Enanta Pharmaceuticals with a score of -0.108. Current assessment reveals the stock is positioned within a rising trend in the short term. Potential change of approximately 12.4% may be seen in the next three months, returns between 2.71% and 31.62%. The 12-month analysis predicts a projected change of -20.6%. The stock's price could fluctuate between negative 67.90% and negative 10.35% over the coming year. Trading volume increased on the last day. Fibonacci and Accumulated Volume support and resistance levels are given, with the support at $7.81 and resistance at $8.39. It has a weekly volatility of 7.31%. Capps Kathleen bought and sold 16115 shares in the company. It has a P/E ratio of -1.83 with a suggested stop-loss at $7.57.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.